Hexarelin (Peptide) : The Potent GH Pulse Initiator, Cardioprotective Peptide, Pituitary Activator

Hexarelin is a powerful synthetic hexapeptide belonging to the growth hormone secretagogue family, designed to stimulate robust pulsatile release of growth hormone from the pituitary. Beyond its endocrine effects, it exhibits remarkable cardioprotective and anti-fibrotic properties, distinguishing it from other members of its class through its unique receptor interactions and tissue-protective actions.

---

1. Overview:

Hexarelin is a synthetic hexapeptide with the amino acid sequence His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH₂ . As a member of the growth hormone-releasing peptide (GHRP) family, it acts on the ghrelin receptor (GHSR-1a) in the pituitary and hypothalamus to stimulate growth hormone (GH) release. Unlike some other GHRPs, hexarelin possesses a unique pharmacological profile characterized by high potency, dose-dependent GH release, and significant actions on the cardiovascular system that appear independent of its GH-releasing properties. Its ability to activate the GH pulse generator makes it a tool for studying somatotroph function and a candidate for addressing GH deficiency syndromes .

---

2. Origin & Common Forms:

Hexarelin is a wholly synthetic compound not found in nature. It is classified as a research peptide and is not approved by the FDA for human therapeutic use as a prescription drug in the United States, although it has been studied in clinical research settings . It is available through chemical synthesis for research purposes and is also encountered in the compounding pharmacy sector for off-label use under clinician supervision .

---

3. Common Supplemental Forms: Standard & Enhanced

· Lyophilized Powder for Injection: The standard form for research and clinical use. It is supplied as a sterile powder that requires reconstitution with bacteriostatic water or sterile saline.

· Compounded Preparations: Available via licensed compounding pharmacies for patients under direct medical supervision.

· Research Grade: Sold as "not for human consumption" for laboratory investigation only.

It is not typically formulated into oral or enhanced delivery systems as standard subcutaneous or intravenous administration is required for reliable bioavailability.

---

4. Natural Origin:

· Synthetic Construct: Hexarelin is a fully man-made peptide. It is structurally distinct from endogenous ghrelin, the natural ligand for the GHS receptor .

· Precursors: Synthesized from protected amino acids using solid-phase peptide synthesis techniques, not derived from natural biological sources.

---

5. Synthetic / Man-made:

· Process: Produced via solid-phase peptide synthesis using a peptide synthesizer. The process involves sequential coupling of protected amino acids (His, D-2-methyl-Trp, Ala, Trp, D-Phe, Lys-NH2) to a solid resin support. After completion of the chain assembly, the peptide is cleaved from the resin, deprotected, and purified using high-performance liquid chromatography (HPLC) .

· Purity: High-purity preparations used in research typically exceed 98-99% purity.

---

6. Commercial Production:

· Precursors: Fmoc-protected amino acids, coupling reagents (e.g., HBTU, DIC), and resin for solid-phase synthesis.

· Process: Large-scale automated peptide synthesis, followed by HPLC purification, lyophilization, and packaging under sterile conditions.

· Quality Control: Research-grade hexarelin is analyzed by mass spectrometry (for molecular weight confirmation) and HPLC (for purity assessment). Pharmaceutical-grade material for clinical studies is manufactured under Good Manufacturing Practice standards.

---

7. Key Considerations:

The Dual Action Profile. Hexarelin exerts effects through at least two distinct mechanisms. First, it binds to the ghrelin receptor (GHSR-1a) in the hypothalamus and pituitary, triggering a potent, dose-dependent surge in GH secretion that mimics the natural physiological pulse . This GH peak occurs approximately 30 minutes after administration and resolves within 240 minutes, closely resembling the body's intrinsic rhythm . Second, hexarelin acts on the heart and blood vessels via a receptor distinct from GHSR-1a, likely involving CD36, to produce direct cardioprotective and anti-apoptotic effects that are independent of circulating GH levels . This dual nature makes it unique: it is both an endocrine modulator and a direct tissue protectant.

---

8. Structural Similarity:

A synthetic hexapeptide (6 amino acids long) sharing the core structural motif of GHRP-6 but with a D-2-methyl-tryptophan residue at position 2, conferring enhanced potency and stability. It belongs to the class of growth hormone secretagogues (GHSs), which includes GHRP-6, GHRP-2, ipamorelin, and the natural ligand ghrelin.

---

9. Biofriendliness:

· Utilization: Administered intravenously or subcutaneously. Subcutaneous bioavailability is approximately 64% in animal models, indicating moderate absorption efficiency .

· Half-Life: Approximately 55 minutes in humans after IV administration. Peak GH levels occur at 30 minutes, returning to baseline by 240 minutes .

· Metabolism & Excretion: Primarily eliminated via biliary excretion, with significant recovery of unchanged peptide in bile (60%) and urine (22%) suggesting resistance to proteolytic degradation . Highest concentrations are found in the kidney, liver, and duodenum .

· Distribution: Volume of distribution at steady state in rats is 744 mL/kg, indicating distribution into extracellular fluids .

· Toxicity: No significant accumulation occurs with repeated administration due to first-order kinetics and dose-independent clearance .

---

10. Known Benefits (Clinically Supported):

· Growth Hormone Secretion: Potently stimulates GH release in a dose-dependent manner. In clinical studies, 2 mcg/kg IV produced mean peak GH concentrations of 55 ng/mL, comparable to maximal GHRH stimulation . Effective in children with idiopathic GH deficiency .

· Cardiac Inotropic Effect: Acute intravenous administration increases left ventricular ejection fraction (LVEF), cardiac output, and cardiac index in healthy volunteers and patients with coronary artery disease. Effects are observed within 30 minutes and persist for up to 60 minutes .

· Cardioprotection Against Ischemia-Reperfusion Injury: Reduces myocardial infarct size in experimental models of ischemia-reperfusion injury via a protein kinase C-dependent mechanism .

· Reduction of Cardiac Fibrosis: Long-term administration in hypertensive animal models decreases myocardial collagen deposition and reverses left ventricular hypertrophy and diastolic dysfunction .

· Anti-Atherosclerotic Effects: Reduces atherosclerotic plaque formation, neointima formation, and vascular smooth muscle cell proliferation in animal models .

---

11. Purported Mechanisms:

· GHSR-1a Activation in Hypothalamus and Pituitary: Binds to ghrelin receptors on somatotroph cells and hypothalamic neurons, leading to GH release. The effect on GH secretion appears to be mediated through the hypothalamus, as patients with hypothalamic-pituitary disconnection show blunted responses .

· Stimulation of the Hypothalamic-Pituitary-Adrenal (HPA) Axis: Hexarelin increases ACTH and cortisol secretion. Studies suggest this may occur through stimulation of arginine vasopressin (AVP) release rather than CRH, as the effect is not augmented by CRH but may involve AVP pathways .

· Direct Cardiac Effects via CD36 and PKC Signaling: In cardiomyocytes, hexarelin activates protein kinase C (PKC) cascades, increases L-type calcium current and intracellular calcium transients, producing positive inotropic effects. It also reduces angiotensin II-induced apoptosis and DNA fragmentation .

· Inhibition of Cardiac Fibroblast Activation: Suppresses transforming growth factor-beta (TGF-β)-induced collagen synthesis and proliferation in cardiac fibroblasts .

· Prolactin and Cortisol Release: Like other GHRPs, hexarelin possesses significant prolactin- and ACTH/cortisol-releasing activity, though prolactin responses are lower than those elicited by TRH .

---

12. Other Possible Benefits Under Research:

· Reduction of Atherosclerosis: Increases serum nitric oxide levels and endothelial nitric oxide synthase expression in the aorta of atherosclerotic animal models .

· Potential Wound Healing: Growth hormone secretagogues are being investigated for tissue repair applications.

· Cognitive Effects (Cautionary): Chronic administration in animal models has shown impaired memory acquisition, particularly in female offspring exposed in utero and in adult female mice, warranting further safety evaluation .

---

13. Side Effects:

· Minor & Transient: Injection site reactions, flushing, headache, dizziness, mild nausea .

· Endocrine-Related: Increased appetite (noted on visual analog scales in clinical studies), water retention, elevated prolactin levels (though lower than TRH-induced release), and transient increases in ACTH/cortisol .

· To Be Cautious About: Receptor desensitization may occur with prolonged use, necessitating cycling strategies to maintain GH responsiveness. Elevated cortisol could be problematic in susceptible individuals. The effect on appetite may complicate use for weight management.

· Serious (Theoretical/Rare): As with any compound that elevates GH/IGF-1, there are theoretical concerns about promoting the growth of existing malignancies. Contraindicated in active cancer, uncontrolled diabetes, pregnancy, and breastfeeding .

---

14. Dosing & How to Take:

· Research/Clinical Dosing: In human studies, intravenous doses of 0.5, 1.0, and 2.0 mcg/kg have been used. The 2.0 mcg/kg dose produces near-maximal GH responses (ED50 approximately 0.5-0.64 mcg/kg) .

· Typical Compounded Dose Range (Off-Label): In clinical practice, common subcutaneous doses range from 100 to 300 mcg once or twice daily, often cycled (e.g., 5 days on, 2 days off) to prevent desensitization .

· How to Take: Subcutaneous injection into the abdomen or thigh using an insulin syringe. Administered on an empty stomach (at least 2 hours after last meal and 30 minutes before eating) to avoid interference from food-induced insulin and nutrient signals.

· Reconstitution: The lyophilized powder should be reconstituted with sterile bacteriostatic water or sterile saline.

---

15. Tips to Optimize Benefits:

· Timing: For maximizing endogenous GH rhythm, administer before bedtime (to augment the natural nocturnal GH pulse) or immediately post-exercise. Avoid administration near meals.

· Cycling: To mitigate receptor desensitization, cycling is a common clinical strategy: 4-8 weeks on followed by 1-2 weeks off .

· Synergistic Combinations: Frequently combined in clinical practice with GHRH analogs (e.g., sermorelin, tesamorelin) or other GHRPs (e.g., ipamorelin) to produce a more physiological GH profile, though this increases complexity and risk.

· Monitoring: Clinician oversight with monitoring of IGF-1 levels, fasting glucose, HbA1c, blood pressure, and cortisol is recommended .

---

16. Not to Exceed / Warning / Interactions:

· Drug Interactions: Caution with insulin or oral hypoglycemics (due to GH's insulin-antagonistic effects). Additive effects with other GH secretagogues.

· Contraindications: Active malignancy; history of cancer (especially breast, prostate, colon); pregnancy or breastfeeding; uncontrolled diabetes mellitus; active acromegaly; severe sleep apnea; significant edema or heart failure without cardiology clearance .

· Medical Conditions: Use with extreme caution in those with hypothalamic-pituitary disease, as responsiveness may be blunted or absent . Patients with cardiovascular disease should clear use with their cardiologist.

---

17. LD50 & Safety:

· Acute Toxicity (LD50): Animal studies have not defined a specific LD50; it is administered in microgram-per-kilogram doses, indicating a wide therapeutic index relative to effective doses.

· Human Safety: In clinical studies, single doses up to 2 mcg/kg IV and repeated doses have been well-tolerated. Long-term safety data in humans beyond short clinical trials is limited. Reproductive toxicity studies in animals show potential adverse effects on ovulation and memory acquisition, raising concerns for chronic or prenatal exposure .

---

18. Consumer Guidance:

· Label Literacy: This is a research peptide. Any legitimate source will label it clearly as "For Research Use Only" or "Not for Human Consumption," or will require a prescription from a licensed medical provider and dispensing by a compounding pharmacy.

· Quality Assurance: Given the proliferation of unregulated research peptide vendors, quality and purity are highly variable. Contamination with endotoxins, incorrect peptide sequence, or degradation products is a serious risk when sourcing from non-reputable suppliers. Third-party testing (HPLC, MS) is essential for research applications.

· Regulatory Status: Hexarelin is not an FDA-approved drug. Its use is restricted to clinical trials and research settings, or off-label prescribing by physicians.

· Manage Expectations: This is a potent GH secretagogue, not a dietary supplement. It produces quantifiable increases in circulating GH levels but is not a substitute for prescription GH replacement therapy for diagnosed GH deficiency without a physician's guidance. The cardioprotective benefits are documented in experimental models but are not established clinical indications. Do not self-source or self-administer peptides without medical supervision.